848777-77-5

Basic information

• Product Name: Cyclohexanecarboxylic acid, 1-[[(1,1-dimethylethyl)sulfonyl]methyl]-
• CAS NO: 848777-77-5
• Molecular Formula: C12H22O4S
• Molecular Weight: 262.37
• Mol File: 848777-77-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Cyclohexanecarboxylic acid, 1-[[(1,1-dimethylethyl)sulfonyl]methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarboxylic acid, 1-[[(1,1-dimethylethyl)sulfonyl]methyl]-(848777-77-5)
• EPA Substance Registry System: Cyclohexanecarboxylic acid, 1-[[(1,1-dimethylethyl)sulfonyl]methyl]-(848777-77-5)

Safety Data

• Hazardous Substances Data: 848777-77-5(Hazardous Substances Data)

Upstream product

• 40195-26-4 1-methoxy-1-trimethylsilyloxymethylenecyclohexane 
• 864185-88-6 C₁₃H₂₄O₂S 
• 4630-82-4 methyl cyclohexylcarboxylate 
• 864185-89-7 C₁₂H₂₂O₂S 

Downstream Products

• 848776-92-1 C₁₂H₂₁NO₃S 
• 865466-24-6 narlaprevir 
• 1208245-85-5 C₁₈H₃₄N₂O₅S 
• 1208245-88-8 C₂₇H₄₇N₃O₆S 
• 1229337-32-9 C₂₆H₄₅N₃O₆S 
• 1256345-29-5 C₃₆H₆₃N₅O₇S 

Relevant articles and documents

ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF β-AMINO-α- HYDROXY AMIDES

Processes useful for the preparation of a Compound of Formula I: Formula (I). Intermediates useful for the preparation of the compound of Formula I, and processes useful for preparing said intermediates are disclosed.

Discovery of narlaprevir (SCH 900518): A potent, second generation HCV NS3 serine protease inhibitor

Boceprevir (SCH 503034), 1, a novel HCV NS3 serine protease inhibitor discovered in our laboratories, is currently undergoing phase III clinical trials. Detailed investigations toward a second generation protease inhibitor culminated in the discovery of narlaprevir (SCH 900518), 37, with improved potency (～10-fold over 1), pharmacokinetic profile and physicochemical characteristics, currently in phase II human trials. Exploration of synthetic sequence for preparation of 37 resulted in a route that required no silica gel purification for the entire synthesis.

3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.